Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the incidence, demographics, and associated conditions of alopecia areata and provides no new clinical findings.

This study identified four genes related to alopecia areata: GIMAP6 and ALOX15 as risk factors, and GALNT6 and HEG1 as protective factors, noting significant validation differences in GALNT6 and HEG1.

This review of interventions for alopecia areata found no significant treatment benefits for hair growth compared to placebo, indicating a need for larger, well-conducted studies.

This review found that patients with alopecia areata may have lower levels of vitamin D, zinc, and folate, but conflicting evidence precludes definitive clinical recommendations for micronutrient supplementation.

This study found that patients with alopecia areata reported worse quality of life and higher anxiety and depression levels compared to those with androgenetic alopecia and healthy controls.

This study found that T-regulatory cells, specifically the FOXP3 CD39 subset, were significantly reduced in both circulation and hair follicles of alopecia areata patients compared to healthy subjects, suggesting potential therapeutic targets.

This study found that Israeli patients with alopecia areata had a higher prevalence of comorbid conditions, including food allergies and chronic spontaneous urticaria, compared to matched controls.

In this study, patients with alopecia areata were found to have a higher risk of stroke over a 3-year follow-up period compared to those without the condition.

This study reported that the IL1A 4-bp indel polymorphism is associated with a reduced risk of alopecia areata in Chinese populations, possibly through miR-122 mediated regulation of IL-1α expression.

This study reported that atypical variants of alopecia areata made up less than 25% of all cases in their specialized trichology unit, suggesting a potential selection bias.

This study found that CD2 could be a potential new therapeutic target for treating patchy-type alopecia areata, suggesting the need for further research into its role.

This review discusses the pathomechanism and pathology of alopecia areata, its classifications, and associated diseases, but reports no new clinical results, highlighting the importance for current and future treatment considerations.

This Cochrane Review protocol aims to evaluate the effectiveness and safety of various treatments for alopecia areata through a network meta-analysis, but no specific study findings are reported yet.

This study found a significant positive association between higher air quality index values and the incidence of alopecia areata, with a clear dose-response relationship observed among the participants.

The study reported that patients with alopecia areata had significantly higher serum levels of IL-17A and IL-2 compared to healthy controls, suggesting these interleukins may play an important role in the disease, though they did not correlate with its severity or duration.

This case report describes a 12-year-old boy with severe atopic dermatitis and comorbid alopecia areata who experienced complete hair regrowth and improved skin condition after 3 months of oral abrocitinib treatment, with no adverse reactions observed during a 1-year follow-up period.

This study suggests that potent topical corticosteroid occlusion may be a safe and effective treatment option for pediatric patients with severe alopecia areata, although further research is needed on its long-term safety and recurrence.

In this study, researchers found that alopecia areata patients show a significant reduction in suppressive regulatory T-cells and an increase in inflammatory T-cell populations, suggesting an immunological imbalance contributing to the disease.

This article reviews the role of the National Alopecia Areata Foundation in promoting research and collaboration to find treatments or a cure for alopecia areata and reports no clinical results.

Medicaid coverage for alopecia areata treatments is inconsistent and often limited.

This study in a California safety net hospital found no apparent increase in alopecia areata incidence among individuals who received COVID-19 vaccination compared to those unvaccinated, with odds ratios indicating a lower risk in the vaccinated group.

This review discusses the clinical characteristics, diagnosis, and treatment of alopecia areata, exploring potential environmental, immunological, and genetic factors involved in its development, but reports no new research findings.

In this study, hair restoration surgery using mini-micrograft techniques successfully improved aesthetic outcomes and patient satisfaction in women with hypotrichosis of the pubis, particularly when preoperative evaluation matched pubic hair design to individual patient preferences.

This study found that dupilumab's effects on alopecia areata varied depending on patients' immune profiles, with Th2-skewed females seeing improvements and Th1-driven males experiencing worsening.

This study found that hair diameter varies significantly within the occipital safe donor area, with thicker hair in the upper sections and thinner hair in the lower sections.

This study found significant differences in hair diameter between males and females across different zones of the safe donor area, which may aid in selecting optimal donor regions for hair transplantation surgeries.

This article reviews the cultural, historical, and marketing influences driving female pubic hair removal and argues it is socially seen as normative for aesthetic, hygienic, erotic, and self-image reasons.

This study found that although both adults and adolescents with alopecia areata experience a significant quality of life impact from ≥50% scalp hair loss, the impact is greater for adolescents, as indicated by their higher Dermatology Life Quality Index scores.

This study found that nonshaven follicular unit extraction is an effective method for pubic hair restoration in women with pubic atrichosis or hypotrichosis, based on high satisfaction scores from both patients and the surgeon.

In this retrospective study of alopecia areata patients across several European countries, researchers observed a notable reduction in SALT scores, but few patients reached or maintained a clinically significant SALT score of ≤20, indicating potentially limited effectiveness of current treatments for extensive hair loss.